- Chemotherapy
- Targeted therapy
Lung Cancer Therapeutics Market size was valued at USD 18,327.8 million in 2023 and is poised to grow at a CAGR of 13.2% from 2024-2030. The market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccine for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in the market.
Study Period
2024-2030Base Year
2023CAGR
13.2%Largest Market
North AmericaFastest Growing Market
Europe
Lung cancer or lung carcinoma is the disease characterized by the abnormal proliferation of tumour cells in the lung tissues. Lung cancer is classified into 3 types namely lung carcinoid tumour, small cell lung cancer, and non-small cell lung cell cancer. Common symptoms associated with the lung cancer include a cough, weight loss, shortness of breath, and chest pains. Smoking and prolonged use of tobacco are the common risk factors for the lung cancer. Lung cancer can be diagnosed by the biopsy performed by using CT-guidance or bronchoscopy. Lung cancer can be treated by radiotherapy, chemotherapy, and surgery.
Increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of lung cancer therapeutics market. Moreover, innovation of newer radiotherapies, a launch of low priced generic drugs, and rise in prevalence of non-small cell lung cancer are expected to propel the market over the forecast period. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the growth of the market.
By Drug Class
By Disease Type
By End User
By Geography
The global lung cancer therapeutics market size was valued at US$ 18,327.9 million in 2023 and is projected to grow at a CAGR of 13.2% from 2024 to 2030
Rising Pollution due to Rapid Industrialization and Rise in the Number of Smokers
Europe is the fastest-growing for lung cancer therapeutics market
1. Executive Summary |
2. Global Lung Cancer Therapeutics Market Introduction |
2.1. Global Lung Cancer Therapeutics Market Taxonomy |
2.2. Global Lung Cancer Therapeutics Market Definitions |
2.2.1. By Treatment Type |
2.2.2. By Disease Type |
2.2.3. By Distribution Channel |
2.2.4. By Region |
3. Global Lung Cancer Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Lung Cancer Therapeutics Market Dynamic Factors - Impact Analysis |
3.6. Global Lung Cancer Therapeutics Market Competition Landscape |
3.7. Epidemiology |
4. Global Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 |
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Lung Cancer Therapeutics Market, By Treatment Type, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.1. Targeted Therapy |
5.1.1. Bevacizumab |
5.1.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.1.3. Market Opportunity Analysis |
5.1.2. Dabrafenib/Trametinib |
5.1.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.2.3. Market Opportunity Analysis |
5.1.3. Erlotinib |
5.1.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3.3. Market Opportunity Analysis |
5.1.4. Osimertinib |
5.1.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.4.3. Market Opportunity Analysis |
5.1.5. Others |
5.1.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.5.3. Market Opportunity Analysis |
5.2. Immunotherapy |
5.2.1. Durvalumab |
5.2.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.1.3. Market Opportunity Analysis |
5.2.2. Nivolumab |
5.2.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.2.3. Market Opportunity Analysis |
5.2.3. Atezolizumab |
5.2.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3.3. Market Opportunity Analysis |
5.2.4. Pembrolizumab |
5.2.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.4.3. Market Opportunity Analysis |
5.3. Chemotherapy |
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Lung Cancer Therapeutics Market, By Disease Type, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
6.1. Non-small Cell Lung Cancer (NSCLC) |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Small Cell Lung Cancer (SCLC) |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Lung Cancer Therapeutics Market Forecast, By Distribution Channel, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Lung Cancer Therapeutics Market Forecast, By Region, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Region, 2024-2030 |
9. North America Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
9.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Targeted Therapy |
9.1.1.1. Bevacizumab |
9.1.1.2. Dabrafenib/Trametinib |
9.1.1.3. Erlotinib |
9.1.1.4. Osimertinib |
9.1.1.5. Others |
9.1.2. Immunotherapy |
9.1.2.1. Durvalumab |
9.1.2.2. Nivolumab |
9.1.2.3. Atezolizumab |
9.1.2.4. Pembrolizumab |
9.1.3. Chemotherapy |
9.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Non-small Cell Lung Cancer (NSCLC) |
9.2.2. Small Cell Lung Cancer (SCLC) |
9.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Hospital Pharmacies |
9.3.2. Retail Pharmacies |
9.3.3. Online Pharmacies |
9.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030 |
9.6. North America Lung Cancer Therapeutics Market Dynamics Trends |
10. Europe Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
10.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Targeted Therapy |
10.1.1.1. Bevacizumab |
10.1.1.2. Dabrafenib/Trametinib |
10.1.1.3. Erlotinib |
10.1.1.4. Osimertinib |
10.1.1.5. Others |
10.1.2. Immunotherapy |
10.1.2.1. Durvalumab |
10.1.2.2. Nivolumab |
10.1.2.3. Atezolizumab |
10.1.2.4. Pembrolizumab |
10.1.3. Chemotherapy |
10.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Non-small Cell Lung Cancer (NSCLC) |
10.2.2. Small Cell Lung Cancer (SCLC) |
10.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Hospital Pharmacies |
10.3.2. Retail Pharmacies |
10.3.3. Online Pharmacies |
10.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Rest of Europe |
10.5. Europe Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030 |
10.6. Europe Lung Cancer Therapeutics Market Dynamics Trends |
11. Asia-Pacific Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
11.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Targeted Therapy |
11.1.1.1. Bevacizumab |
11.1.1.2. Dabrafenib/Trametinib |
11.1.1.3. Erlotinib |
11.1.1.4. Osimertinib |
11.1.1.5. Others |
11.1.2. Immunotherapy |
11.1.2.1. Durvalumab |
11.1.2.2. Nivolumab |
11.1.2.3. Atezolizumab |
11.1.2.4. Pembrolizumab |
11.1.3. Chemotherapy |
11.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Non-small Cell Lung Cancer (NSCLC) |
11.2.2. Small Cell Lung Cancer (SCLC) |
11.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Hospital Pharmacies |
11.3.2. Retail Pharmacies |
11.3.3. Online Pharmacies |
11.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. China |
11.4.2. India |
11.4.3. Japan |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030 |
11.6. Asia-Pacific Lung Cancer Therapeutics Market Dynamics Trends |
12. Latin America Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
12.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Targeted Therapy |
12.1.1.1. Bevacizumab |
12.1.1.2. Dabrafenib/Trametinib |
12.1.1.3. Erlotinib |
12.1.1.4. Osimertinib |
12.1.1.5. Others |
12.1.2. Immunotherapy |
12.1.2.1. Durvalumab |
12.1.2.2. Nivolumab |
12.1.2.3. Atezolizumab |
12.1.2.4. Pembrolizumab |
12.1.3. Chemotherapy |
12.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Non-small Cell Lung Cancer (NSCLC) |
12.2.2. Small Cell Lung Cancer (SCLC) |
12.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Hospital Pharmacies |
12.3.2. Retail Pharmacies |
12.3.3. Online Pharmacies |
12.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030 |
12.6. Latin America Lung Cancer Therapeutics Market Dynamics Trends |
13. Middle East and Africa Lung Cancer Therapeutics Market Analysis, 2019-2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
13.1. Treatment Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Targeted Therapy |
13.1.1.1. Bevacizumab |
13.1.1.2. Dabrafenib/Trametinib |
13.1.1.3. Erlotinib |
13.1.1.4. Osimertinib |
13.1.1.5. Others |
13.1.2. Immunotherapy |
13.1.2.1. Durvalumab |
13.1.2.2. Nivolumab |
13.1.2.3. Atezolizumab |
13.1.2.4. Pembrolizumab |
13.1.3. Chemotherapy |
13.2. Disease Type Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Non-small Cell Lung Cancer (NSCLC) |
13.2.2. Small Cell Lung Cancer (SCLC) |
13.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Hospital Pharmacies |
13.3.2. Retail Pharmacies |
13.3.3. Online Pharmacies |
13.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2024-2030 |
13.6. MEA Lung Cancer Therapeutics Market Dynamics Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. F. Hoffmann-La Roche Ltd |
14.2.2. Eli Lilly and Company |
14.2.3. Celgene Corporation |
14.2.4. AstraZeneca plc |
14.2.5. Pfizer, Inc. |
14.2.6. Sanofi SA |
14.2.7. Novartis AG |
14.2.8. Bristol Myers Squibb |
14.2.9. Merck MSD |
14.2.10. Millennium Pharmaceuticals, Inc. |
15. Research Methodology |
16. Key Assumptions and Acronyms |